ESTRO 2024 - Abstract Book

S2261

Clinical - Upper GI

ESTRO 2024

Conclusion:

The optimal oncological approach in patients with non-metastatic CESCC remains to be fully defined [1,2]. Multidisciplinary management is of pivotal importance, targeting adequate patient selection and treatment tailoring. Meanwhile, studies on predictive biomarkers and new systemic therapies are eagerly awaited; randomized trials should be attempted at high-volume centers.

Keywords: Esophageal cancer, IMRT, Trimodality therapy

References:

1) Hulshof MCCM, Geijsen ED, Rozema T, Oppedijk V, Buijsen J, Neelis KJ, Nuyttens JJME, van der Sangen MJC, Jeene PM, Reinders JG, van Berge Henegouwen MI, Thano A, van Hooft JE, van Laarhoven HWM, van der Gaast A. Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). J Clin Oncol. 2021 Sep 1;39(25):2816-2824. doi: 10.1200/JCO.20.03697. Epub 2021 Jun 8. PMID: 34101496. 2)Hoeben A, Polak J, Van De Voorde L, Hoebers F, Grabsch HI, de Vos-Geelen J. Cervical esophageal cancer: a gap in cancer knowledge. Ann Oncol. 2016 Sep;27(9):1664-74. doi: 10.1093/annonc/mdw183. Epub 2016 Apr 26. PMID: 27117535.

2632

Digital Poster

SBRT for Hepatocellular Carcinoma: Real World Outcomes After National Commissioning in England